White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression

Cortex

Volumn 52, Issue 1, 2014, Pages 98-112

  Novak, Marianne J U ^a,b   Seunarine, Kiran K ^c   Gibbard, Clare R ^b,c   Hobbs, Nicola Z ^b   Scahill, Rachael I ^b   Clark, Chris A ^c   Tabrizi, Sarah J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Caudate; Diffusion; DTI (diffusion tensor imaging); Huntington's disease; TBSS (tract based spatial statistics)

Indexed keywords

ADULT; ARTICLE; BRAIN FORNIX; BRAIN REGION; BRAIN SIZE; CAG REPEAT; CAPSULA INTERNA; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM INFECTION; CINGULUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS CALLOSUM; DISEASE COURSE; DISEASE SEVERITY; EXTERNAL CAPSULE; FEMALE; FRACTIONAL ANISOTROPY; GENETIC MARKER; HUMAN; HUNTINGTON CHOREA; INFERIOR LONGITUDINAL FASCICULI; MALE; MEAN DIFFUSIVITY; NEUROIMAGING; PREDICTION; QUANTITATIVE ANALYSIS; SHORT PERFORATING FIBER; SUPERIOR LONGITUDINAL FASCICULI; WHITE MATTER;

CAUDATE; DIFFUSION; DTI (DIFFUSION TENSOR IMAGING); HUNTINGTON'S DISEASE; TBSS (TRACT-BASED SPATIAL STATISTICS);

ADULT; ATROPHY; CAUDATE NUCLEUS; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NEUROIMAGING; ORGAN SIZE;

EID: 84895524943     PISSN: 00109452     EISSN: 19738102     Source Type: Journal    
DOI: 10.1016/j.cortex.2013.11.009     Document Type: Article

References (45)

1. Aylward E.H., Brandt J., Codori A.M., Mangus R.S., Barta P.E., Harris G.J. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994, 44:823-828.
2. Beaulieu C. The basis of anisotropic water diffusion in the nervous system - a technical review. NMR in Biomedicine 2002, 15:435-455.
3. Bohanna I., Georgiou-Karistianis N., Egan G.F. Connectivity-based segmentation of the striatum in Huntington's disease: vulnerability of motor pathways. Neurobiology of Disease 2011, 42:475-481.
4. Bohanna I., Georgiou-Karistianis N., Hannan A.J., Egan G.F. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Research Reviews 2008, 58:209-225.
5. Bohanna I., Georgiou-Karistianis N., Sritharan A., Asadi H., Johnston L., Churchyard A., et al. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging and Behavior 2011, 5:171-180.
6. Della Nave R., Ginestroni A., Tessa C., Giannelli M., Piacentini S., Filippi M., et al. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. American Journal of Neuroradiology 2010, 31:1675-1681.
7. Douaud G., Behrens T.E., Poupon C., Cointepas Y., Jbabdi S., Gaura V., et al. Invivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage 2009, 46:958-966.
8. Dumas E.M., van den Bogaard S.J., Ruber M.E., Reilman R.R., Stout J.C., Craufurd D., et al. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Human Brain Mapping 2012, 33(1):203-212.
9. Gunning-Dixon F.M., Head D., McQuain J., Acker J.D., Raz N. Differential aging of the human striatum: a prospective MR imaging study. American Journal of Neuroradiology 1998, 19:1501-1507.
10. Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Movement Disorders 1996, 11:136-142.
11. Kloppel S., Draganski B., Golding C.V., Chu C., Nagy Z., Cook P.A., et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008, 131:196-204.
12. Kloppel S., Henley S.M., Hobbs N.Z., Wolf R.C., Kassubek J., Tabrizi S.J., et al. Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience 2009, 164:205-219.
13. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics 2004, 65:267-277.
14. Magnotta V.A., Kim J., Koscik T., Beglinger L.J., Espinso D., Langbehn D., et al. Diffusion tensor imaging in preclinical Huntington's disease. Brain Imaging and Behavior 2009, 3:77-84.
15. Mascalchi M., Lolli F., Della Nave R., Tessa C., Petralli R., Gavazzi C., et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004, 232:867-873.
16. Muller H.P., Glauche V., Novak M.J., Nguyen-Thanh T., Unrath A., Lahiri Swales N., et al. Stability of white matter changes related to Huntington's disease in the presence of imaging noise: a DTI study. PLoS Currents Huntington Disease 2011, Jun 7. Edition 1. 10.1371/currents.RRN1232.
17. Novak M.J.U., Tabrizi S.J. Huntington's disease. BMJ 2010, 340:c3109.
18. Patenaude B., Smith S.M., Kennedy D.N., Jenkinson M.A. Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage 2011, 56:907-922.
19. Paulsen J.S., Magnotta V.A., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., et al. Brain structure in preclinical Huntington's disease. Biological Psychiatry 2006, 59:57-63.
20. Penney J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Annals of Neurology 1997, 41:689-692.
21. Pierpaoli C., Jezzard P., Basser P.J., Barnett A., Di Chiro G. Diffusion tensor MR imaging of the human brain. Radiology 1996, 201:637-648.
22. Ravina B., Romer M., Constantinescu R., Biglan K., Brocht A., Kieburtz K., et al. The relationship between CAG repeat length and clinical progression in Huntington's disease. Movement Disorders 2008, 23:1223-1227.
23. Raz N., Rodrigue K.M., Kennedy K.M., Head D., Gunning-Dixon F., Acker J.D. Differential aging of the human striatum: longitudinal evidence. American Journal of Neuroradiology 2003, 24:1849-1856.
24. Reading S.A., Yassa M.A., Bakker A., Dziorny A.C., Gourley L.M., Yallapragada V., et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Research 2005, 140:55-62.
25. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
26. Rosas H.D., Lee S.Y., Bender A.C., Zaleta A.K., Vangel M., Yu P., et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical. NeuroImage 2010, 49:2995-3004.
27. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Movement Disorders 2006, 21:1317-1325.
28. Rosenblatt A., Liang K.Y., Zhou H., Abbott M.H., Gourley L.M., Margolis R.L., et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006, 66:1016-1020.
29. Shoulson I., Fahn S. Huntington's disease: clinical care and evaluation. Neurology 1979, 29:1-3.
30. Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage 2006, 31:1487-1505.
31. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 2004, 23(Suppl 1):S208-S219.
32. Smith S.M., Zhang Y., Jenkinson M., Chen J., Matthews P.M., Federico A., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 2002, 17:479-489.
33. Sritharan A., Egan G., Johnston L., Horne M., Bradshaw J., Bohanna I., et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry 2009, 81:257-262.
34. Stoffers D., Sheldon S., Kuperman J., Goldstein J., Corey-Bloom J., Aron A.R. Contrasting gray and white matter changes in preclinical Huntington disease. Neurology 2010, 74:1208-1216.
35. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology 2009, 8:791-801.
36. Tabrizi S.J., Reilmann R., Roos R.A., Durr A., Leavitt B., Owen G., et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology 2012, 11:42-53.
37. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology 2011, 10:31-42.
38. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72(6):971-983.
39. Thieben M.J., Duggins A.J., Good C.D., Gomes L., Mahant N., Richards F., et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002, 125:1815-1828.
40. Ulug A.M., Moore D.F., Bojko A.S., Zimmerman R.D. Clinical use of diffusion-tensor imaging for diseases causing neuronal and axonal damage. American Journal of Neuroradiology 1999, 20:1044-1048.
41. Vandenberghe W., Demaerel P., Dom R., Maes F. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. Journal of Neurology 2009, 256:109-114.
42. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology 1985, 44:559-577.
43. Weaver K.E., Richards T.L., Liang O., Laurino M.Y., Samii A., Aylward E.H. Longitudinal diffusion tensor imaging in Huntington's disease. Experimental Neurology 2009, 216:525-529.
44. Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:3498-3503.
45. Whitwell J.L., Crum W.R., Watt H.C., Fox N.C. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. American Journal of Neuroradiology 2001, 22(8):1483-1489.